770 results on '"Macaulay R"'
Search Results
52. PBI27 Multistakeholder Recommendations for LONG-TERM Sustainability of the Biosimilar Market in Europe: A Delphi Panel Consensus
53. PCN265 CHARACTERISATION OF MANAGED ACCESS AGREEMENTS UNDER THE NICE CANCER DRUGS FUND
54. PNS133 HTA BEST PRACTICE - NICE FAST TRACK APPROVALS: 2-YEAR REPORT CARD
55. PNS73 THE RIPPLE EFFECT – HOW PMPRB REFORMS COULD IMPACT DRUG PRICES GLOBALLY
56. PRO61 EVIDENCE OF VERY LOW UTILIZATION OF MEDICINES RECOMMENDED UNDER THE NICE HIGHLY SPECIALIZED TECHNOLOGY PATHWAY
57. PMU80 THE ITALIAN INNOVATION ACCELERATION? BEST PRACTICE LESSONS OF REIMBURSEMENT INCENTIVES FOR INNOVATIVE PRODUCTS
58. PNS126 COMPARING EARLY ACCESS TO UNLICENSED MEDICINES IN UK, FRANCE, AND SWEDEN: CONSISTENT PRINCIPLES BUT INCONSISTENT OUTPUTS
59. PMU85 MISSION IMPOSSIBLE? REIMBURSEMENT SUCCESS WITH FAILED PHASE III TRIAL
60. PNS141 PATIENT INVOLVEMENT IN REIMBURSEMENT DECISION-MAKING - HOW ARE THEY INVOLVED? HOW SHOULD THEY BE INVOLVED?
61. PCN261 CAR-T THERAPIES: REIMBURSEMENTS ABOUND, BUT WITH STRINGS ATTACHED
62. PNS121 DOES THE CHOICE OF INDEPENDENT EXPERT COMMITTEE AFFECT ICER OUTCOMES?
63. PMU89 NEW AIFA INNOVATION ALGORITHM: 2 YEAR REPORT CARD
64. PNS128 STILL EXCELLING? AN ASSESSMENT OF SOFTWARE USED IN NICE SINGLE TECHNOLOGY APPRAISALS AND ICER REPORTS IN 2019
65. HT1 EVIDENCE OF METHODOLOGICAL HETEROGENEITY IN THE NICE APPRAISAL PROCESS DEPENDING ON ERG: A REVIEW OF SURVIVAL EXTRAPOLATION APPROACHES IN ONCOLOGY
66. Sociolect/Social Class
67. Central nervous system graft-versus-host disease presenting with granulomatous encephalitis
68. Abstracts
69. November 2000: 13 year old girl with back pain and leg weakness
70. PMU104 NAVIGATING DIVERGENCE: ACCOMMODATING THE MULTITUDE OF NEW PAYER BODIES IN EMERGING MARKETS
71. PMU95 IS THERE REGIONAL VARIATION IN WORSE AND SLOWER COST/QALY HTA OUTCOMES FOR COMBINATION PRODUCTS INVOLVING TWO VS. ONE MANUFACTURER?
72. PNS128 READY FOR PRIME TIME? HAVE EMA PRIME DESIGNATIONS SUPPORTED ACCELERATED REGULATORY APPROVAL AND PATIENT ACCESS?
73. PBI70 WILL CAR-T CELL THERAPIES CHANGE HOW DRUGS ARE PRICED AND REIMBURSED?
74. PRO112 THE HST TEST: GOOD, BETTER, BEST?
75. PNS227 THE NOT-NICE ACCESS PATHWAY: NHS ENGLAND SPECIALISED COMMISSIONING
76. PCN374 BETTER LATE THAN NEVER: THE DYNAMICS OF NICE DECISION-MAKING UNDER THE NEW MODEL OF THE CDF
77. PRO106 A NEW MAJOR MARKET ACCESS CHALLENGE - KEEPING THE ROI WINDOW OPEN?
78. PMU64 UNLOCKING ACCESS FOR TRANSFORMATIONAL CAR-T CELL AND GENE THERAPIES. ARE BIOSIMILARS THE KEY?
79. PNS258 ABBREVIATED HTA PATHWAYS, EXPEDITING PATIENT ACCESS TO NOVEL TREATMENTS?
80. PNS281 DO SPANISH TPRS AFFECT THE NATIONAL PRICING AND REIMBURSEMENT OF DRUGS?
81. PCN387 ARE NICE APPRAISAL COMMITTEES BEING CONSISTENT IN THEIR IMPLEMENTATION OF THE END OF LIFE CRITERION?
82. PRS48 UNLOCKING THE ACCESS CHALLENGES TO COPD
83. PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT?
84. PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?
85. PNS206 AIM FOR THE STARS, REACH THE MOON? A SIMPLE STRATEGY TO IMPROVE ADDITIONAL BENEFIT OUCTOMES IN GERMANY?
86. PMU76 EVIDENCE OF BETTER HTA OUTCOMES FOR COMBINATION PRODUCTS INVOLVING ONLY A SINGLE COMPANY IN EUROPE
87. PBI32 PUTTING THE CAR-T BEFORE THE HORSE: HAVE ATMPS EMERGED BEFORE COHERENT REIMBURSEMENT PROCESSES HAVE BEEN ESTABLISHED?
88. PNS267 WINNING BEYOND THE REGULATOR. COMPARING THE VALUE OF DIFFERENT DATA TYPES FROM PAYER AND CLINICIAN PERSPECTIVES TO SUPPORT PRESCRIBING AND REIMBURSEMENT
89. PDG77 THE EMERGENCE OF THERAPEUTIC RADIOPHARMACEUTICALS. DO THE EXTRA COSTS OUTWEIGH THE GAINS?
90. PMU46 TRIAL SEPARATION - IS THERE A TRUE GENDER DISPARITY IN CLINICAL TRIALS?
91. PMD27 IS NATIONAL HEALTH TECHNOLOGY ASSESSMENT AN OPTIMAL MODEL FOR MEDICAL DEVICE REIMBURSEMENT? CASE STUDY: FRANCE
92. PMU74 HEALTH TECHNOLOGY ASSESSMENT IN BULGARIA – 3 YEAR REPORT CARD
93. PNS96 NICE SOCIAL MEDIA - IMPACT OF AD-HOC PUBLIC COMMENTS ON HST RECOMMENDATIONS
94. PNS84 EAMS VS. ATU: COMPARING EARLY ACCESS TO UNLICENSED MEDICINES IN UK AND FRANCE
95. PNS170 NICE END OF LIFE - SURVIVAL CRITERION: STRICT IMPLEMENTATION OR PRAGMATIC FLEXIBILITY?
96. PNS42 R NICE LAGGING BEHIND THE WORLD?
97. PCN199 THE IMPACT OF PCODR COMING UNDER THE REMIT OF CADTH: 3 YEAR UPDATE
98. PBI25 THE BIOSIMILAR RACE IN US AND EUROPE: NOT ALL HURDLES ARE CREATED EQUAL
99. PMU61 VARIABLE BIOSIMILAR COVERAGE ACROSS US COMMERCIAL PLANS
100. PNS101 YOU REAP WHAT YOU SOW; EUNETHTA COMING TO FRUITION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.